Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-06-01 DOI:10.1186/s12885-025-14357-9

Zhirui Zeng, Yun Ke, Fei Huang, Hangyi Li, Xiaomin Zhang, Dahuan Li, Yingmin Wu, Tengxiang Chen, Yunhuan Zhen

{"title":"Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.","authors":"Zhirui Zeng, Yun Ke, Fei Huang, Hangyi Li, Xiaomin Zhang, Dahuan Li, Yingmin Wu, Tengxiang Chen, Yunhuan Zhen","doi":"10.1186/s12885-025-14357-9","DOIUrl":null,"url":null,"abstract":"Background and purpose: Colorectal cancer (CRC) is the third most prevalent malignancy in the gastrointestinal tract and the second leading cause of cancer-related deaths. Despite the identification of numerous biomarkers, their non-specific distribution across different cell types complicates the development of targeted therapies. Therefore, this study aims to identify specific biomarkers for CRC and utilize them for the development of targeted therapies.Methods: Single-cell RNA sequencing and machine learning were used to analyze INF2 localization in CRC tissues and its prognostic value. Immunohistochemistry, cell biology assays, and computational docking were employed to assess INF2's clinical significance and identify inhibitors.Results: INF2 was identified as a key prognostic marker in CRC, with elevated expression in advanced-stage tissues. Knockdown of INF2 inhibited CRC cell proliferation and mobility. DiosMetin 7-O-β-D-Glucuronide, a natural compound, selectively inhibited INF2-high CRC cells with minimal toxicity to normal cells.Conclusion: INF2 is a CRC-specific biomarker associated with poor prognosis. DiosMetin 7-O-β-D-Glucuronide, as an INF2 inhibitor, shows promise as a targeted therapeutic agent for CRC treatment.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"982"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128233/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14357-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: Colorectal cancer (CRC) is the third most prevalent malignancy in the gastrointestinal tract and the second leading cause of cancer-related deaths. Despite the identification of numerous biomarkers, their non-specific distribution across different cell types complicates the development of targeted therapies. Therefore, this study aims to identify specific biomarkers for CRC and utilize them for the development of targeted therapies.

Methods: Single-cell RNA sequencing and machine learning were used to analyze INF2 localization in CRC tissues and its prognostic value. Immunohistochemistry, cell biology assays, and computational docking were employed to assess INF2's clinical significance and identify inhibitors.

Results: INF2 was identified as a key prognostic marker in CRC, with elevated expression in advanced-stage tissues. Knockdown of INF2 inhibited CRC cell proliferation and mobility. DiosMetin 7-O-β-D-Glucuronide, a natural compound, selectively inhibited INF2-high CRC cells with minimal toxicity to normal cells.

Conclusion: INF2 is a CRC-specific biomarker associated with poor prognosis. DiosMetin 7-O-β-D-Glucuronide, as an INF2 inhibitor, shows promise as a targeted therapeutic agent for CRC treatment.

查看原文本刊更多论文

以7-O-β- d -葡糖苷靶向INF2：结直肠癌治疗的新策略

背景和目的：结直肠癌（CRC）是胃肠道中第三大最常见的恶性肿瘤，也是癌症相关死亡的第二大原因。尽管鉴定了许多生物标志物，但它们在不同细胞类型中的非特异性分布使靶向治疗的发展复杂化。因此，本研究旨在确定CRC的特异性生物标志物，并利用它们开发靶向治疗。方法：采用单细胞RNA测序和机器学习技术分析结直肠癌组织中INF2的定位及其预后价值。采用免疫组织化学、细胞生物学和计算对接来评估INF2的临床意义并确定抑制剂。结果：INF2被确定为结直肠癌的关键预后标志物，在晚期组织中表达升高。敲低INF2抑制结直肠癌细胞的增殖和迁移。DiosMetin 7-O-β-D-Glucuronide是一种天然化合物，可选择性抑制高inf2的CRC细胞，对正常细胞的毒性很小。结论：INF2是与不良预后相关的crc特异性生物标志物。DiosMetin 7-O-β-D-Glucuronide作为一种INF2抑制剂，有望成为结直肠癌的靶向治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.